-+ 0.00%
-+ 0.00%
-+ 0.00%

StoneX Maintains Speculative Buy on Intensity Therapeutics, Lowers Price Target to $8

Benzinga·11/06/2026 14:06:32
Listen to the news
StoneX analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the price target from $12 to $8.